Newsbenzinga
FDA Raises No Concerns Over Auxora Safety Data, CalciMedica Advances Trial
· Published
Article summary
FDA raises no objections to CalciMedica revised Phase 2 KOURAGE trial, allowing Auxora dosing to resume for acute kidney injury.
An excerpt from the original article.
Comments —
Loading comments…